San Jose, CA, May 8, 2023

Biomed Industries, Inc. (Biomed) announced today that it has entered into an Engagement Agreement with JP Morgan Securities, LLC to serve as its exclusive financial advisor for a potential acquisition of the Company.

With the completion of Biomed’s Phase 2A clinical trial, which demonstrated significant efficacy in maintaining cognitive function in patients with mild to moderate Alzheimer’s Disease (AD), the Company is well positioned to execute its Phase 2B and 3 trials and present itself as an acquisition target for large pharmaceutical companies seeking a viable treatment for AD.

“Where drugs targeting Beta Amyloid as the cause of AD have consistently showed little to no clinical benefit, our Neurogenesis approach has shown real results”, said Lloyd L. Tran, Chairman and CEO of Biomed. He continued: ”We believe that our Neurogenesis drug, NA-831, acting alone or in conjunction with drugs from Biogen, Eisai, Eli Lily, and others, is an exciting new pathway for the treatment of Alzheimer’s Disease. Working with the JP Morgan M&A team allows us to engage with large pharmaceutical companies in a much more strategic manner.”

About Biomed Industries, Inc.

Biomed Industries™, Inc. is a bio-pharmaceutical company committed to the development and commercialization of new drug therapeutics for unmet needs. Biomed is a leading innovator, having discovered a new family of clinical stage drugs for the treatment of Alzheimer’s disease. The Company is also developing new applications of AI for drug discovery, clinical trials recruitment and execution, and other mission critical areas in the pharmaceutical and medical device industry. For more information, please visit https://www.biomedind.com

- CONTACT:

Biomed Industries, Inc.
San Jose, CA 95131 USA
Tel. 800-824-5135
Michael Willis
Email: media@biomedind.com